Similarly, we demonstrated that the NOX2 inhibitor apocynin increased angiogenesis and reduced the NLRP3 inflammasome in the acute phase of stroke but suppressed angiogenesis and promoted NLRP3 inflammasome activation in the later stage of stroke. The gene discussed is CYBB; the disease is stroke disorder.